12.73

2.68% -0.35

Nurix Therapeutics Inc (NRIX)

Overview News Price History Option Chain Financials Discussions Forecast

Nurix Therapeutics Inc stock is currently priced at $12.73, with a 24-hour trading volume of 927.74K. It has seen a -2.68% decreased in the last 24 hours and a -14.33% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $12.91 pivot point. If it approaches the $12.21 support level, significant changes may occur.

Previous Close:

$13.08

Open:

$13.4

24h Volume:

927.74K

Market Cap:

$777.39M

Revenue:

$80.89M

Net Income/Loss:

$-144.73M

P/E Ratio:

-4.2862

EPS:

-2.97

Net Cash Flow:

$-83.87M

1W Performance:

+2.99%

1M Performance:

-14.33%

6M Performance:

+129.16%

1Y Performance:

+35.43%

1D Range:

$12.61

$13.40

52W Range:

$4.22

$18.12

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name

Nurix Therapeutics Inc

Sector

Healthcare (1210)

Industry

Biotechnology (681)

Phone

415-660-5320

Address

1700 Owens Street, Suite 205, San Francisco

Employee

103

Twitter

Next Earnings Date

2024-05-20

Latest SEC Filings

NRIX's Discussions on Twitter

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-09-23	Initiated	Barclays	Overweight
Feb-28-23	Initiated	Oppenheimer	Outperform
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Dec-29-21	Initiated	H.C. Wainwright	Buy
Oct-14-21	Initiated	SVB Leerink	Outperform
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-30-21	Resumed	Piper Sandler	Overweight
Apr-30-21	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform
Aug-18-20	Initiated	JP Morgan	Overweight
Aug-18-20	Initiated	Needham	Buy
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	Stifel	Buy

View All

Nurix Therapeutics Inc Stock (NRIX) Latest News

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire Inc.

Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study

Zacks Investment Research

Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Benzinga

Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket

Benzinga

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

GlobeNewswire Inc.

Nurix Therapeutics Inc Stock (NRIX) Financials Data

Nurix Therapeutics Inc (NRIX) Revenue 2024

NRIX reported a revenue (TTM) of $80.89 million for the quarter ending February 29, 2024, a +94.02% rise year-over-year.

Nurix Therapeutics Inc (NRIX) Net Income 2024

NRIX net income (TTM) was -$144.73 million for the quarter ending February 29, 2024, a +18.94% increase year-over-year.

Nurix Therapeutics Inc (NRIX) Cash Flow 2024

NRIX recorded a free cash flow (TTM) of -$83.87 million for the quarter ending February 29, 2024, a +52.53% increase year-over-year.

Nurix Therapeutics Inc (NRIX) Earnings per Share 2024

NRIX earnings per share (TTM) was -$2.66 for the quarter ending February 29, 2024, a +24.65% growth year-over-year.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.